Covestor LTD Eagle Pharmaceuticals, Inc. Transaction History

Covestor LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$4.63 - $15.21 $143 - $471	31 Added 36.47%	116 $1,000
Q3 2023 Nov 13, 2023	BUY	$15.21 - $22.88 $349 - $526	23 Added 37.1%	85 $1,000
Q2 2023 Aug 11, 2023	BUY	$17.74 - $31.87 $319 - $573	18 Added 40.91%	62 $1,000
Q1 2023 May 15, 2023	SELL	$25.06 - $34.09 $526 - $715	-21 Reduced 32.31%	44 $1,000
Q4 2022 Feb 13, 2023	BUY	$24.98 - $39.77 $1,149 - $1,829	46 Added 242.11%	65 $1,000
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $501 - $895	19 New	19 $1,000
Q2 2022 Aug 10, 2022	SELL	$41.26 - $51.35 $4,579 - $5,699	-111 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$44.58 - $52.6 $2,942 - $3,471	66 Added 146.67%	111 $6,000
Q4 2021 Feb 10, 2022	BUY	$45.82 - $56.9 $2,061 - $2,560	45 New	45 $2,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

Stay updated on Covestor LTD with notifications on news.